Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 10INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 307Recurrence 64Neoplasms 32Neoplasms, Plasma Cell 17Lymphoma, Non-Hodgkin 14Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Vomiting 11Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Nausea 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Ovarian Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Hematologic Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Paraproteinemias 5Lung Neoplasms 5Leukemia 5Small Cell Lung Carcinoma 4Renal Insufficiency 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Plasmacytoma 4Lymphoma, Follicular 4Hematologic Diseases 4Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3

Interventions

Bevacizumab 187Fluorouracil 150Leucovorin 135Cetuximab 127Irinotecan 114Oxaliplatin 108pembrolizumab 96Capecitabine 82IFL protocol 53Panitumumab 43Nivolumab 43regorafenib 42Folfox protocol 39Gemcitabine 30trifluridine tipiracil drug combination 27Cisplatin 24Carboplatin 24atezolizumab 23Pemetrexed 20Paclitaxel 20Drug Therapy 20130-nm albumin-bound paclitaxel 17Trastuzumab 14encorafenib 13Trifluridine 13Ipilimumab 13HMPL-013 13tislelizumab 12spartalizumab 11Docetaxel 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Neoplasms × Dexamethasone × Clear all
NCT02649790 2025-03-19

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Karyopharm Therapeutics Inc

Phase 1/2 Completed
277 enrolled
GastrointestinalMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT00601172 2018-01-17

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

GlaxoSmithKline

Phase 3 Completed
710 enrolled 29 charts
Gastrointestinal

Nausea, Vomiting, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡